STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Clinical trials for STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7 trials appear
Sign up with your email to follow new studies for STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for tough melanoma? drug targets Cancer's growth signals
Disease control OngoingThis study tested a drug called ibrutinib in 18 people with stage IV melanoma that had not responded to previous treatments. Ibrutinib works by blocking certain enzymes that help cancer cells grow. The main goal was to see if the drug could shrink tumors, and researchers also loo…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 08:02 UTC
-
Could a Two-Drug combo tame advanced melanoma?
Disease control OngoingThis study tested whether adding a drug called GM-CSF (sargramostim) to the immunotherapy ipilimumab helps people with advanced melanoma that cannot be surgically removed. About 245 participants were randomly assigned to receive ipilimumab alone or with GM-CSF. The main goal was …
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:57 UTC
-
Experimental combo targets Cancer's Self-Eating process
Disease control OngoingThis early-phase trial tests the safety and best dose of combining two drugs—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, or prostate or kidney cancer. The goal is to see if blocking a process called autophagy can help kill more cancer cells. Abo…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:53 UTC
-
New combo aims to boost immune attack on tough melanoma
Disease control OngoingThis early-phase study tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ibrutinib (which blocks certain enzymes that help cancer grow)—in people with advanced melanoma that cannot be surgically removed. The main goals…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 07:52 UTC
-
New combo therapy targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase trial studies the safety and best dose of two drugs, riluzole and sorafenib, given together to adults with advanced solid tumors or melanoma that has spread and is no longer responding to standard treatments. The goal is to find a dose that limits side effects wh…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:26 UTC
-
New combo therapy shows promise in fighting advanced skin cancer
Disease control OngoingThis study looked at 88 people with advanced melanoma (skin cancer that has spread) that cannot be removed by surgery. Researchers tested two different doses of the drug ipilimumab, either alone or combined with high-dose interferon, to see which approach works better at stopping…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:24 UTC
-
Triple threat: new drug cocktail targets tough melanoma
Disease control OngoingThis study tests whether combining three drugs—an immunotherapy (nivolumab) with two targeted therapies—can shrink or control advanced melanoma that has spread or can't be removed. It includes people with a specific gene mutation (BRAF V600) whose cancer got worse after prior tre…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 07:24 UTC
-
New drug cocktail aims to starve and shrink Hard-to-Treat cancers
Disease control OngoingThis early-phase study tested a combination of two drugs, cediranib and selumetinib, in 19 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drugs could block tumor growth by cutting off blood…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
Triple threat: new combo aims to boost melanoma survival
Disease control OngoingThis study tests whether adding a drug called sargramostim to the standard immunotherapy combination of nivolumab and ipilimumab helps people with advanced melanoma live longer. About 600 adults with stage III or IV melanoma that cannot be surgically removed will receive either t…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New combo therapy shows promise for melanoma patients who failed previous treatment
Disease control OngoingThis study tests whether combining two immunotherapy drugs—talimogene laherparepvec (T-VEC) and pembrolizumab (Keytruda)—can shrink tumors in people with advanced melanoma that has stopped responding to standard anti-PD1/L1 therapy. About 43 adults with stage III or IV melanoma t…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Could drug holidays work for advanced melanoma? new study investigates
Disease control OngoingThis study tests whether taking a break from two targeted cancer drugs (dabrafenib and trametinib) works as well as taking them continuously for people with advanced melanoma that has a specific BRAF mutation. About 280 participants with stage III or IV melanoma that cannot be su…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 18, 2026 11:59 UTC
-
Major trial tests which immune drug best stops melanoma comeback
Disease control OngoingThis study tested whether the immunotherapy drug ipilimumab works better than high-dose interferon alfa-2b at preventing melanoma from coming back after surgery. About 1,673 patients with high-risk stage III–IV melanoma that was fully removed took part. The main goal was to see w…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Inhaled therapy shows promise for lung metastases
Disease control OngoingThis study tests an inhaled form of a protein called interleukin-2 (IL-2) to treat cancers that have spread to the lungs, such as melanoma, kidney cancer, and sarcoma. The goal is to find the safest dose and see if it can shrink tumors. About 70 adults with advanced cancer and lu…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
New drug shows promise in slowing advanced melanoma
Disease control OngoingThis study tests a drug called dinaciclib in 72 people with stage IV melanoma that has spread. The drug works by blocking enzymes that help cancer cells grow. The goal is to see if it can shrink tumors or slow the disease, and to check for side effects.
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 07, 2026 18:43 UTC
-
Supercharged immune cells take on melanoma in early trial
Disease control OngoingThis early-phase study tests a new way to fight advanced melanoma. Doctors take a patient's own immune cells (T-cells), modify them in a lab to resist a tumor-blocking signal (TGF-beta), and return them to the body along with a drug (IL-2) that boosts their activity. The goal is …
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 01, 2026 15:58 UTC